A detailed history of Bank Of America Corp transactions in Exelixis, Inc. stock. As of the latest transaction made, Bank Of America Corp holds 1,164,178 shares of EXEL stock, worth $30.8 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,164,178
Previous 1,027,798 13.27%
Holding current value
$30.8 Million
Previous $24.4 Million 7.26%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$20.34 - $23.73 $2.77 Million - $3.24 Million
136,380 Added 13.27%
1,164,178 $26.2 Million
Q1 2024

May 15, 2024

SELL
$20.17 - $23.93 $11.4 Million - $13.5 Million
-563,634 Reduced 35.42%
1,027,798 $24.4 Million
Q4 2023

Feb 14, 2024

BUY
$19.25 - $24.13 $7 Million - $8.78 Million
363,873 Added 29.64%
1,591,432 $38.2 Million
Q2 2023

Aug 14, 2023

SELL
$18.17 - $20.48 $3.36 Million - $3.79 Million
-185,132 Reduced 13.1%
1,227,559 $23.5 Million
Q1 2023

May 12, 2023

BUY
$16.3 - $19.41 $5.19 Million - $6.19 Million
318,685 Added 29.13%
1,412,691 $27.4 Million
Q4 2022

Feb 10, 2023

SELL
$14.96 - $17.39 $5.35 Million - $6.22 Million
-357,741 Reduced 24.64%
1,094,006 $17.5 Million
Q3 2022

Nov 14, 2022

SELL
$15.68 - $22.27 $1.19 Million - $1.7 Million
-76,198 Reduced 4.99%
1,451,747 $22.8 Million
Q2 2022

Aug 12, 2022

BUY
$17.44 - $23.16 $5.49 Million - $7.29 Million
314,735 Added 25.94%
1,527,945 $31.8 Million
Q1 2022

May 16, 2022

BUY
$17.03 - $22.67 $5.47 Million - $7.29 Million
321,466 Added 36.05%
1,213,210 $27.5 Million
Q4 2021

Feb 08, 2022

BUY
$15.84 - $21.88 $2.39 Million - $3.31 Million
151,112 Added 20.4%
891,744 $16.3 Million
Q3 2021

Nov 15, 2021

BUY
$16.3 - $21.14 $2.25 Million - $2.92 Million
138,004 Added 22.9%
740,632 $15.7 Million
Q2 2021

Sep 13, 2021

BUY
$17.95 - $25.56 $10.8 Million - $15.4 Million
602,628 New
602,628 $11 Million

Others Institutions Holding EXEL

About EXELIXIS, INC.


  • Ticker EXEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 321,832,000
  • Market Cap $8.51B
  • Description
  • Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...
More about EXEL
Track This Portfolio

Track Bank Of America Corp Portfolio

Follow Bank Of America Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Bank Of America Corp , based on Form 13F filings with the SEC.

News

Stay updated on Bank Of America Corp with notifications on news.